Ruka hadi maudhui makuu

Condition · 3 treatment paths

Triple-Negative Breast Cancer

Triple-negative breast cancer is a breast cancer that lacks oestrogen receptors, progesterone receptors and HER2. Hormone and HER2-targeted treatments therefore do not work.

Severe
Request opinion View roster

Send your imaging + plan. Board-reviewed opinion in 5–10 working days.

Ilisasishwa mwisho: Jinsi tunavyokusanya na kukagua taarifa

Linear accelerator used for radiotherapy in a cancer treatment room
Treatment paths
3Treatment paths
Specialties
1Specialties
Typical severity
SevereTypical severity

About triple-negative breast cancer

What to know

It often shows as a lump in the breast and tends to grow quickly, affecting younger women and those with BRCA1 gene changes more often. Diagnosis uses mammography, ultrasound and a needle biopsy, with receptor testing confirming the type, and scans for spread. It carries a higher early risk of returning than other types, but responds well to chemotherapy.

Treatment combines surgery, chemotherapy and, for many, immunotherapy with a PD-1 drug such as pembrolizumab. Chemotherapy is often given before surgery to shrink the tumour. Surgery is either breast-conserving or mastectomy with sentinel node biopsy, and radiotherapy often follows. Genetic testing guides decisions. People sometimes travel abroad for immunotherapy or second opinions, but delays in starting treatment should be avoided.

Pre-flight workup

Tests to have already done

  • Biopsy pathology confirming grade, Ki-67 and receptor status (ER, PR, HER2), ideally with a repeat HER2 test if borderline.
  • Breast MRI, mammogram and ultrasound with images, showing tumour size and spread to the axilla.
  • Staging scans such as CT or PET-CT, for larger or node-positive disease.
  • Genetic testing results for BRCA1 and BRCA2 and other genes, which affect surgery and drug choices.
  • A full list of chemotherapy and immunotherapy given, with doses, dates and any reactions.

Second opinion

When to get a second look

  • Surgery has been scheduled first, without discussing chemotherapy before the operation.
  • BRCA testing has not been done and may affect your surgical and drug choices.
  • You had chemotherapy before surgery and cancer remains in the removed tissue, which may qualify you for more treatment.
  • The cancer has spread, or you want to know whether immunotherapy is suitable for your tumour.

Talking to your doctor

Questions to ask

  1. What are the stage and grade of my cancer, and are the receptor results confirmed?
  2. Should chemotherapy and immunotherapy be given before surgery?
  3. Do I need a genetic test, and how would the result change treatment?
  4. Is breast conservation possible, or is mastectomy advisable?
  5. What happens if cancer remains after chemotherapy?
  6. What follow-up and imaging will I need, and when is the risk of recurrence highest?

Outlook

Realistic prognosis

Triple-negative breast cancer has a higher chance of returning than other types, mostly in the first three to five years, but many patients, particularly with early-stage disease, are cured. Response to chemotherapy before surgery is a strong predictor: patients with no remaining cancer have a much better outlook. Immunotherapy and newer drugs have improved results. Outlook depends on stage, node involvement and response to treatment, and BRCA carriers need tailored advice.

01 · Specialties

Specialties that treat Triple-Negative

Specialists Doctors who treat triple-negative breast cancer Cross-hospital roster across 1+ relevant specialties. View roster

Diagnostic workup

Before you pick a hospital, get the workup right

Severe — workup typically within 48–72 hours

Picking the right treatment is downstream of a complete diagnosis. Skip steps here and the destination surgeon usually re-orders them anyway — at higher cost and another week on the ground.

  1. Confirm the diagnosis on imaging or labs

    For triple-negative breast cancer, plan on the workup your home doctor would order anyway — typically a recent specialist consult plus the imaging / labs the destination team will need to quote accurately. Anything older than 90 days usually gets re-done.
  2. See a oncology specialist locally first

    An in-person clinical exam at home — even a single consult — costs little and dramatically improves the destination plan. Bring back: written impression, recommended procedure, surgical-risk class, and any contra-indications.
  3. Send us the file for a free second opinion

    Two surgeons in our medical panel review the workup independently. They tell you whether they'd operate, watch, or refer — even if that means recommending against travel.
  4. Pick a path with timeline + cost in writing

    Once a treatment is the right call, we line up 2–3 hospital options with itemized quotes, surgeon profiles, and a travel timeline. You hold the file — switch hospitals or step away at any point.

03 · Treatment paths

Treatment options

All treatments

Where to be treated

Triple-Negative Breast Cancer treatment by destination

Get a panel match

04 · FAQ

Common questions about triple-negative breast cancer

Why is triple-negative breast cancer treated differently?

Because it lacks oestrogen, progesterone and HER2 receptors, hormone therapy and HER2 drugs do not work, so chemotherapy, and in many cases immunotherapy, are the main systemic treatments.

Should I have genetic testing?

Usually yes. A significant share of triple-negative cancers are linked to BRCA1 or BRCA2 changes, which affect treatment and family risk.

Is chemotherapy given before or after surgery?

Often before, for larger or node-positive tumours, because response to treatment guides further therapy. Smaller tumours may have surgery first.

Clinical context

Working up triple-negative breast cancer properly

A condition like triple-negative breast cancer is rarely well-served by jumping straight to treatment shopping. The sequence below is what a oncology specialist would expect to see completed — and the absence of any step is the right cue to delay travel decisions.

Diagnostic workup, in sequence

  1. First-line clinical assessment

    History, physical exam, and risk-factor review by a senior generalist or oncology specialist. Symptoms list, family history, prior workup notes, and current medication list should travel with the patient.

  2. Standard imaging + labs

    Baseline blood work, condition-specific imaging (ultrasound / X-ray / MRI / CT — depending on indication), and ECG / pulmonary function as relevant. Bring digital copies of any prior imaging — saves repeat scans and the cost that goes with them.

  3. Specialist diagnostic workup

    Procedure-specific tests — biopsy, cardiac catheterisation, endoscopy, or genetic / molecular profiling depending on the suspected diagnosis. Done at the centre that will treat, ideally, so results integrate cleanly into the treatment plan.

  4. Multidisciplinary review (where indicated)

    Cancer, complex cardiac, transplant, and rare-disease cases should be reviewed by a multidisciplinary panel — surgical, medical, imaging, and pathology — before any treatment commits. Single-discipline plans for complex disease are a quality red flag.

When to escalate urgently

  • Acute worsening of established symptoms — sudden chest pain, shortness of breath at rest, neurological deficit, severe bleeding, persistent high fever.
  • Loss of consciousness, severe persistent vomiting, or any focal neurological event.
  • Symptoms in the early hours of onset that fit a time-sensitive treatment window (stroke, MI, sepsis) — every hour costs outcome.
  • If you are travelling internationally for treatment and develop these symptoms in transit, divert to the nearest emergency department; do not wait to reach the planned destination.

Before you book international travel

  • Confirm your specific diagnosis is fully worked up before you commit to a treatment plan abroad. Travelling for the workup is fine; travelling for treatment without the workup done is not.
  • Get your case reviewed remotely by the destination centre's team before you book flights — credible international patient programs review imaging + reports before they confirm the surgical plan.
  • Bring a digital + physical copy of your full medical record: imaging on USB drive in DICOM format, labs in PDF, current medication list with dosages, allergies, and any prior surgical reports.
  • Plan for longer recovery + post-discharge therapy continuation before you fly — the surgery itself is rarely the bottleneck.
  • Confirm that follow-up imaging and any necessary in-person reviews can be done at home — a treatment plan that requires repeat international trips is more burdensome (and more expensive) than the headline procedure.
Jinsi ukurasa huu ulivyoandaliwa

Mbinu na viwango vya uhariri

This triple-negative breast cancer overview is written by the editorial team from published Oncology sources and lists 3 treatment options offered by hospitals on our network. The page shows its last-updated date. Clinical descriptions are editorial — your treating clinician confirms what's right for your specific case.

  1. Taarifa za hospitali. Maelezo ya hospitali yanakusanywa kutoka vyanzo vya umma na tovuti za hospitali. Uidhinishaji (JCI, NABH na mengine) huonyeshwa pale tulipo na rekodi. Daima omba hospitali cheti chake cha sasa.
  2. Sifa za madaktari. Sifa, utaalamu na wasifu hutoka wasifu wa daktari hospitalini. Leseni hukaguliwa kwenye rejista ya baraza la kitaifa la madaktari tu pale wasifu unapoonyesha alama ya "Leseni imehakikiwa" yenye tarehe.
  3. Bei. Viwango vya bei ni vya kukadiria, vimekusanywa kutoka orodha za bei na vifurushi vya hospitali na huonyeshwa na tarehe ya mwisho ya kusasishwa. Unacholipa ni kile kilichoandikwa kwenye nukuu ya hospitali.
  4. Maandishi ya kitabibu. Imeandikwa na timu ya wahariri ya Medcasts kutoka vyanzo vya kliniki vilivyochapishwa. Isipokuwa ukurasa umetaja mhakiki kwa jina, haujakaguliwa na daktari.
  5. Uhuru. Hospitali haziwezi kulipa ili kubadilisha nafasi yao kwenye kurasa zetu.
Vyanzo vya taarifa za ukurasa huu
Peer-reviewed clinical guidelines (NCCN, ESMO, ESC, AHA, NICE — by indication)WHO ICD-11 condition classificationNational medical society treatment protocolsJCI accreditation registry

Triple-Negative Breast Cancer

Continue evaluating triple-negative breast cancer care

Condition overview is one entry. These hubs route the same care decision via specialty, surgeon, treatment, and destination — including the doctors actively treating triple-negative breast cancer.

Hatua inayofuata · Triple-Negative Breast Cancer

Free second opinion on your Triple-Negative case.

Share imaging and the current plan. Multidisciplinary board returns a written opinion within 5–10 working days — no obligation to travel.

Pata makadirio ya bei bureMakadirio ya kina kutoka hospitali zilizoidhinishwa, bila malipo Maoni ya pili ya daktari bureMtaalamu anapitia ripoti zako Ongea na mratibuWhatsApp, barua pepe au simu